PASS of Paediatric Patients Initiating Selumetinib

RecruitingOBSERVATIONAL
Enrollment

125

Participants

Timeline

Start Date

May 23, 2022

Primary Completion Date

May 23, 2028

Study Completion Date

May 23, 2028

Conditions
Neurofibromatosis Type 1
Trial Locations (45)

Unknown

RECRUITING

Research Site, Vienna

RECRUITING

Research Site, Amiens

RECRUITING

Research Site, Angers

RECRUITING

Research Site, Bordeaux

RECRUITING

Research Site, Lille

RECRUITING

Research Site, Lyon

RECRUITING

Research Site, Marseille

RECRUITING

Research Site, Paris

RECRUITING

Research Site, Rennes

RECRUITING

Research Site, Strasbourg

RECRUITING

Research Site, Toulouse

RECRUITING

Research Site, Tours

TERMINATED

Research Site, Villejuif

RECRUITING

Research Site, Dresden

RECRUITING

Research Site, Duisburg

RECRUITING

Research Site, Hamburg

RECRUITING

Research Site, München

RECRUITING

Research Site, Tübingen

RECRUITING

Research Site, Petah Tikva

RECRUITING

Research Site, Ramat Gan

RECRUITING

Research Site, Tel Aviv

RECRUITING

Research Site, Florence

RECRUITING

Research Site, Genova

RECRUITING

Research Site, Milan

RECRUITING

Research Site, Padua

RECRUITING

Research Site, Pavia

RECRUITING

Research Site, Roma

RECRUITING

Research Site, Torino

RECRUITING

Research Site, Trieste

RECRUITING

Research Site, Rotterdam

RECRUITING

Research Site, Lisbon

TERMINATED

Research Site, Porto

RECRUITING

Research Site, Barcelona

RECRUITING

Research Site, Esplugues de Llobregat

RECRUITING

Research Site, Madrid

RECRUITING

Research Site, Málaga

RECRUITING

Research Site, Santiago de Compostela

RECRUITING

Research Site, Seville

RECRUITING

Research Site, Basel

RECRUITING

Research Site, Bern

RECRUITING

Research Site, Lausanne

RECRUITING

Research Site, Sankt Gallen

RECRUITING

Research Site, London

RECRUITING

Research Site, Manchester

RECRUITING

Research Site, Newcastle

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY